First Ascent created a groundbreaking Software as a Medical Device (SaMD) service that is disrupting the cancer diagnosis process to prodigiously improve therapy plan effectiveness and drive significantly better patient outcomes! The current state of the art in tumor profiling fails >70% of cancer patients. Our SaMD is proven to significantly outperform all current tumor profiling services. First Ascent's SaMD service, powered by our proprietary AI, designs patient-centric cancer drug combinations that shut down the patient's cancer. Our SaMD combines deep drug and tumor profiling, with AI analysis, and delivers a comprehensive report in 3-4 weeks. We test 120+ drugs on the patient’s cancer cells and add in DNA and RNA data. Then, our proprietary AI platform builds combination therapy plans tailored to the patient. Finally, we test for toxicity the combination plans to de-risk the suggested therapy plan for the patient and to build the necessary confidence for the prescribing clinician. Our SaMD is provided through a HIPAA-compliant cloud and is essentially a SaaS and services model that delivers a critical medical answer. FDA approval is NOT required for our SaMD. The majority of companies providing current tumor profiling services also do not have FDA approval, nor are they looking to get approved. We launch this new product in March/April 2022 with first revenue expected in April/May 2022. We already have several luminary physician ready to begin using this service after launch. Their pipeline of patients alone will help us attain our year 1 revenue goal for this product and allow us to immediately begin focusing on the larger market. Our mission is to fundamentally transform the way cancer treatment plans are developed for all patients.